Lapatinib and trastuzumab combination shrinks HER2-positive cancer

被引：0
|
作者：
Coles, Charlotte [1 ]
机构：
[1] Cambridge Univ Hosp NHS Trust, Cambridge, England
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2016年 / 77卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [41] Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis
    Friedman, Marissa D.
    Lacouture, Mario
    Dang, Chau
    CLINICAL BREAST CANCER, 2016, 16 (03) : E69 - E74
  • [42] PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
    Guerin, Mathilde
    Rezai, Keyvan
    Isambert, Nicolas
    Campone, Mario
    Autret, Aurelie
    Pakradouni, Jihane
    Provansal, Magali
    Camerlo, Jacques
    Sabatier, Renaud
    Bertucci, Francois
    Charafe-Jauffret, Emmanuelle
    Hervieu, Alice
    Extra, Jean-Marc
    Viens, Patrice
    Lokiec, Francois
    Boher, Jean-Marie
    Goncalves, Anthony
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 28 - 36
  • [43] Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
    Li, Yi
    Gong, Chengcheng
    Lu, Qianyi
    Zhou, Zhaochun
    Luo, Ting
    Li, Wei
    Li, Gang
    Ge, Rui
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Role of trastuzumab in the combination treatment for a HER2-positive trastuzumab-resistant gastric cancer xenograft model
    Shu, Sei
    Yamashita-Kashima, Yoriko
    Yanagisawa, Mieko
    Moriya, Yoichiro
    Harada, Naoki
    CANCER RESEARCH, 2015, 75
  • [45] New ADC Shrinks HER2-Positive Tumors
    Leslie, Mitch
    CANCER DISCOVERY, 2019, 9 (09) : 1151 - 1152
  • [46] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Zhifei Li
    Huan Zhao
    Huihui Hu
    Haili Shang
    Yongjing Ren
    Wenhui Qiu
    Hao Su
    Huifang Lyu
    Xiaobing Chen
    Chinese Journal of Cancer Research, 2024, 36 (03) : 306 - 321
  • [47] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [48] 'Simply stunning' - trastuzumab in HER2-positive breast cancer
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) : 631 - 634
  • [49] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Li, Zhifei
    Zhao, Huan
    Hu, Huihui
    Shang, Haili
    Ren, Yongjing
    Qiu, Wenhui
    Su, Hao
    Lyu, Huifang
    Chen, Xiaobing
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (03)
  • [50] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Heo, Young-A
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2019, 14 (06) : 749 - 758
12345